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a multi-faceted behavioural trait involving neurally and psy-
chologically diverse elements. We discuss the signiﬁcance
of this heterogeneity for clinical disorders expressing impul-
sive behaviour and the pivotal contributionmade by the brain
dopamine and serotonin systems in the aetiology and treat-
ment of behavioural syndromes expressing impulsive symp-
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In the broadest terms, impulsivity describes poor self-
control, characterised by making decisions quickly, without
forethought or regard for potential consequences (Durana
and Barnes, 1993; Evenden, 1999a; Moeller et al., 2001;
Winstanley et al., 2006a; Dalley et al., 2011). The impor-
tance of impulsivity in decision-making, child development
and neuropsychiatric disorders has long been recognised
(Hollander and Cohen, 1996).
In the past several decades, the notion that impulsivity
may play a central role in the pathogenesis of neuropsy-
chiatric disorders has become increasingly popular.
Impulsivity has been proposed to contribute to a wide
range of psychopathology, including: bipolar disorder
(BD) (Swann, 2009); attention deﬁcit hyperactivity disor-
der (ADHD) (Winstanley et al., 2006a); borderline person-
ality disorder (BPD) (Bornovalova et al., 2005); alcohol
and substance dependence (Ersche et al., 2010); patho-
logical behaviours triggered by Parkinson’s disease (PD)
medication (Housden et al., 2010); as well as suicidality,
a feature of several diﬀerent disorders (Dougherty et al.,
2004; Klonsky and May, 2010). However, the precise def-
inition of the term ‘‘impulsivity’’, and how it is deﬁned oper-
ationally, varies greatly across studies; as a result
drawing clear conclusions on the inﬂuence of monoamine
transmission in impulsivity is extremely challenging.
In this article we begin by outlining what is meant by
the term impulsivity, in particular how it is measured in
the laboratory, and how its conceptualisation has chan-
ged over time from a unitary description to a multi-factorial
construct comprising several aspects of behaviour thatd.
Fig. 1. Schematic representation of (A) 5-choice serial reaction time task, (B) delay discounting task and (C) stop-signal task. Each ﬁgure shows a
representation, from above, of the 5-choice task (A) or operant-conditioning chamber (B, C). Blue arrows indicate correct responses and outcomes,
red arrows indicate incorrect responses and outcomes and grey arrows indicate the outcome following a non-response. The 5-CSRTT requires
subjects to restrain from responding while waiting for a cue predictive of reward. Trials are initiated by subjects entering a food magazine (leftmost
panel). After a 5 s interval has elapsed, a brief light stimulus is presented on a random basis in one of ﬁve open apertures. A nose-poke response
made before the onset the stimulus is classiﬁed as ‘impulsive’ or premature and results in a 5 s timeout period (2nd panel from left). A response in
the illuminated aperture is deemed ‘correct’ and results in the delivery of a single reward pellet in the food magazine (3rd panel from left). Responses
in a non-illuminated aperture or a failure to respond within a 5 s response window are classed as ‘incorrect’ and ‘omission’ trials and initiate a 5 s
timeout period. In the delay discounting task (B), subjects make a choice between responding on a lever for an immediate, but low magnitude
reward (left lever), or on a lever for a larger but delayed reward (right lever). Impulsivity is assessed by preference for the immediate low magnitude
reward. In the stop-signal task (C), rats begin each trial with a nose poke in the central food magazine. The response phase of the trial begins with a
left lever press. Following this, a rapid response on the right lever is classiﬁed ‘correct’ on Go trials, but classiﬁed as ‘incorrect’ on stop-signal trials
(20% of trials in which a brief tone is played before the right lever press is completed). Conversely, inhibition of right lever press is classiﬁed as
‘correct’ on stop-signal trials but ‘incorrect’ on go trials.
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experiments performed in both animals and humans that
support a role for the monoamine neurotransmitters dopa-
mine (DA) and serotonin (5-HT) in inﬂuencing certain
aspects of impulsivity. We end by discussing whether
impulsivity remains a useful term, other than in the broad-
est terms, and make some recommendations for future
research.
The measurement of impulsivity: animals
In experimental animals, diﬀerent aspects of impulsivity
can be measured using computerised behavioural para-
digms that are often based on equivalent tasks in humans
(see Fig. 1). Traditionally, these are divided into paradigms
that assess diﬀerent aspects of response inhibition involv-
ing actions that are premature, mistimed or diﬃcult to sup-
press, and paradigms that assess actions that fail to take
into account other possible options or outcomes, and
hence may be sub-optimal. In the latter case ‘impulsive
choice’ is generally assessed by delay discounting tasks,
in which subjects are trained to choose between small
immediate rewards and larger but delayed rewards
(Cardinal et al., 2001; Pothuizen et al., 2005). Impulsive
subjects show delay aversion and a high preference for
small immediate rewards. In the case of ‘impulsive
response’ paradigms, subjects are trained to suppress a
response made pre-potent by its association with reward.
Prototypical paradigms in this category include the stop-
signal reaction time task (SSRT: Eagle et al., 2008); the
5-choice serial reaction time task (5-CSRTT: Robbins,
2002); the go/no-go task (Harrison et al., 1999); and
delayed response tasks such as diﬀerential reinforcement
of low rates of responding (DRL: Evenden, 1999a). Note
that these distinct forms of impulsivity are not dissimilar to
the constructs of ‘restraint’ and ‘cancellation’, respectively,
derived from the human literature and deﬁned by the
inability of an individual to withhold a strong behavioural
tendency or to cancel an on-going action (Schachar
et al., 2007).
The measurement of impulsive choice, which captures
elements of waiting impulsivity (or delay aversion), can be
empirically derived by the so-called indiﬀerence point
whereby small immediate and large delayed rewards are
chosen with equal frequency (Ainslie, 1975; Mazur and
Coe, 1987). In a variant of this procedure the dimension
of waiting is replaced by that of reinforcer uncertainty
(e.g. St Onge and Floresco, 2010). Thus, in a procedurally
similar manner to temporal discounting tasks, subjects
trained on probabilistic discrimination tasks must choose
between two response options; one delivering a smaller
reward with high (often 100%) probability, the other
delivering a larger reward with varying probabilities over
blocks of trials (Zeeb et al., 2009). Both forms of impulsive
discounting behaviour potentially involve overlapping
decision processes about the relative value of delayed or
uncertain rewards (Dalley et al., 2011).
Impulsive response is typically assessed in experi-
mental animals by measuring the reaction time to stop a
response that has already been initiated. This form of
response inhibition is normally measured using the SSRT
where subjects must restrain from responding on a smallproportion of trials when a stop-signal is presented (Eagle
et al., 2008). The response to be inhibited is made pre-
potent by its high frequency and fast execution and is
strongly inﬂuenced by the delay between the initiation of
the response and onset of the stop-signal; stopping being
more diﬃcult when the stop-signal is delayed than when it
occurs immediately. As there is no clearly observable
behavioural endpoint for a successful stop response,
the SSRT is typically estimated within the theoretical
framework of the ‘race’ model, which assumes that ‘go’
and ‘stop’ processes proceed independently from one
another (Logan, 1994). Not dissimilar to the SSRT, the
go/no-go task assesses the ability of subjects to withhold
a pre-potent response on a small subset of discrete
‘no-go’ trials, which are signalled by a discriminative sen-
sory cue (Harrison et al., 1999).
In both the go/no-go and SSRT paradigms an explicit
signal is used to indicate a subset of trials requiring inhibi-
tion; the absence of a response on such trials is reinforced.
However, in other motor inhibition tasks such as the
5-CSRTT (see Fig. 1A), there are no trials with an explicit
signal to inhibit responding, nor any feedback that a trial
has been successfully inhibited. The basic conﬁguration
of the 5-CSRTT is analogous to the continuous perfor-
mance test in humans, a neuropsychological procedure
used to assess sustained and selective attention and
requires subjects (usually mice or rats) to detect the spatial
location of brief visual stimuli presented in one of ﬁve
recesses in an operant chamber (Robbins, 2002). Impul-
sivity is measured on this task by the number of premature
or anticipatory responses made before the onset of the tar-
get stimulus and increases when the pre-stimulus interval
is lengthened. It is related to impulsivity on DRL sched-
ules, in which subjects are trained to withhold responding
until a set delay has elapsed (Evenden, 1999a).
The measurement of impulsivity: humans
In humans, impulsivity is most commonly measured using
self-report questionnaires, including the Barratt Impulsive-
ness Scale (BIS), the Urgency, Premeditation, Persever-
ance and Sensation Seeking (UPPS) Impulsive
Behaviour Scale, the Impulsiveness Venturesomeness
and Empathy Questionnaire; and the Lifetime History of
Impulsive Behaviours (Eysenck and Eysenck, 1991;
Patton et al., 1995; Whiteside and Lynam, 2001; Schmidt
et al., 2004). These questionnaires recognise the multi-
factorial nature of impulsivity; for example, the BIS-11 is
split into three subscales, attentional, motor and non-
planning impulsiveness, which arise from factor analysis
(Patton et al., 1995). Nonetheless, scores on factors with-
in each test are commonly correlated, to some extent sup-
porting the notion of impulsivity as a unitary phenomenon.
Numerous behavioural tests of impulsivity in humans
have also been proposed, in some cases mirroring those
developed in experimental animals. Assessments include
(among others): temporal discounting; stop-signal reac-
tion time (Logan, 1994); information sampling tests
(Kagan et al., 1964; Clark et al., 2006); the tendency to
make commission errors (false alarms) or premature
responses on a go/no-go or continuous performance test,
sometimes expressed in the ‘‘criterion’’ (beta) statistic
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Todorov, 1999); and gambling or risk-taking tests
(Bechara et al., 1994; Rogers et al., 1999). That quite dif-
ferent cognitive constructs are entailed in each of these
tests suggests from the outset that quite diﬀerent features
of behaviour are being assessed. Temporal-discounting
measures tolerance to delays for ﬁnancial rewards, though
typically over hypothetical timescales of days and weeks,
as opposed to real timescales of seconds in studies in
experimental animals. Similar to the test in rodents
described above, SSRT indexes how quickly an individual
is able to stop a movement once it has already been initi-
ated. Criterion statistics assess an individual’s general
tendency to make a response, independent of the ability
to discriminate between targets and distracters, mirroring
the measurement of the ability to withhold a prepotent
response on equivalent tests in animals. Performance on
decision-making tests can indicate sensitivity to probabil-
ity, or to ﬁnancial gains and losses, similar to recently-
developed tests in animals (Zeeb et al., 2009). Information
sampling tests assess the degree of certainty required
before a choice is made; to our knowledge no comparable
tasks to these yet exist in the animal literature.
How do such behavioural measures relate to ques-
tionnaire-based indices of impulsivity, and do they them-
selves represent the same underlying cognitive
construct? Reynolds et al. (2006) performed the most
comprehensive investigation of this important question
to date, taking questionnaire measures of impulsivity
along with performance on tests of SSRT, go/no-go, delay
discounting and risk-taking in around 100 healthy volun-
teers. Despite high correlations between diﬀerent ques-
tionnaire measures of impulsivity, the authors reported
only one statistically signiﬁcant correlation between ques-
tionnaire and behavioural measures, which was below
r= 0.3. Factor analysis of the behavioural measures
revealed two independent latent variables: one corre-
sponded to the ‘‘impulsive response’’ measures (stop sig-
nal; go/no-go); the other corresponded to the ‘‘impulsive
choice’’ measures (delay discounting; risk taking). This
pattern might not be surprising, since the respective tests
loading onto each factor shared a response format (reac-
tion times versus choices versus questionnaire), which
would be predicted to reduce shared variance between
the diﬀerent measurement types. Nonetheless, the corre-
lations identiﬁed were suﬃciently low for the authors of
this study to conclude that a unitary construct of ‘‘impul-
sivity’’ does not exist, and that ‘‘impulsive choice’’ and
‘‘impulsive response’’ behavioural measures tap into dif-
ferent cognitive processes.
Other studies using comparable designs have simi-
larly failed to ﬁnd any great degree of correspondence
between questionnaire and behavioural measures of
impulsivity (Swann et al., 2002; Lane et al., 2003;
Zermatten et al., 2005; Dom et al., 2007). Some positive
relationships have been reported (Moeller et al., 2002;
Meda et al., 2009), especially in one study with a very
large sample that included several personality question-
naires as well as a temporal-discounting questionnaire
(Kirby and Finch, 2010), though even in this latter study
the loading of the temporal discount k parameter wasweak. In general, the correlation coeﬃcients linking
behavioural and questionnaire measures of impulsivity
rarely exceed r= 0.4, though this might be expected gi-
ven the diﬀerent sources of error potentially contributing
to the diﬀerent measurement formats. Hence, it might
not be surprising that only the largest studies are able to
identify statistically signiﬁcant relationships between
questionnaire and behavioural measures of impulsivity.
However, it should be noted that studies investigating this
issue using a diﬀerent strategy, dividing subjects into
groups according to whether they scored ‘‘high’’ or ‘‘low’’
on impulsivity questionnaires (or simply by using a med-
ian split analysis), have tended to ﬁnd signiﬁcant eﬀects
more consistently. For example, ‘‘high’’ impulsive subjects
have been reported to perform worse on tests of decision-
making (Crean et al., 2000; Franken et al., 2008) and to
have longer SSRTs (Logan et al., 1997). Importantly,
many of the above studies did not take a measurement
of intelligence quotient, a potentially important confound-
ing variable.
To summarise, impulsivity appears to be a multi-
factorial construct; questionnaire measurements
conducted in humans may not reﬂect behavioural
measurements in either humans or experimental animals
(see Evenden, 1999b). As outlined in the rest of the
review, these apparent dissociations in the measurement
of impulsivity are supported by diﬀerent neurochemical
inﬂuences on diﬀerent impulsivity subtypes.DOPAMINE AND SEROTONIN INFLUENCES ON
IMPULSIVITY IN ANIMALS
Research on the neurochemical basis of impulsivity in
experimental animals began in earnest with the seminal
work of Soubrie´ (1986). After integrating the literature
on the eﬀects of drugs on the brain serotonergic systems
Soubrie´ concluded that 5-HT has a special role in modu-
lating the expression of punished behaviour. Drugs which
decreased 5-HT function such as anxiolytics, for example,
were found to reinstate behaviour in rats that previously
was suppressed by a mild electric shock (Tye et al.,
1977). However, rather than suggesting a common under-
lying eﬀect on anxiety, Soubrie´ postulated that 5-HT plays
a speciﬁc role in mediating behavioural inhibition, speciﬁ-
cally in situations of conﬂict between a rewarded ‘‘go’’
response and a punished ‘‘no-go’’ response. Over the last
25 years considerable progress has been made in deﬁn-
ing the role of 5-HT in diﬀerent forms of impulsivity and
there is growing recognition that such behaviour is addi-
tionally and critically regulated by the neurotransmitter
DA.The dopamine systems
DA inputs to the forebrain originate from cell bodies
located in the substantia nigra zona compacta and ventral
tegmental area (see Fig. 2A) giving rise to the nigrostria-
tal, mesolimbic and mesocortical systems (Dahlstroem
et al., 1964). Based on the clinical eﬃcacy of stimulant
drugs that boost brain DA function it is axiomatic to postu-
late that DA plays a signiﬁcant role in the aetiology and
Fig. 2. Distribution of dopamine (A) and serotonin (B) neurotransmitters in the human brain. Diagrams show the distribution of cell bodies in the
ventral tegmental area/substantia nigra (DA) and raphe´ nuclei (5-HT) together with their ascending projections (arrows) to structures in
diencephalon and telencephalon. The main eﬀects of depleting or boosting DA (orange arrows) and 5-HT (red arrows) neurotransmission in the
brain on motor impulsivity (e.g. SSRT), premature responses (e.g. 5-choice serial reaction time task) and delay discounting are summarised in the
panels on the right, which are based on a consensus of pre-clinical and clinical experimental psychopharmacology studies. Upward and downward
arrows denote increased and decreased impulsivity, respectively. Horizontal bidirectional arrows indicate no eﬀect of the manipulation unless
otherwise speciﬁed. Note that complexities exist in the eﬀects of DA and 5-HT receptor agonists and antagonists on each form of impulsivity that
depend in some cases on baseline variation in impulsive behaviour (see text for more details). L-DOPA increases delay discounting impulsivity in
humans whilst amphetamine and other stimulants increase impulsivity when delays to reinforcement are unsignalled. ⁄5-HT depletion increases
delay discounting in humans but this eﬀect is controversial in animals. Figure adapted from Fig. 4.3 and Fig. 4.5; Biological Psychology: An
Introduction to Behavioural, Cognitive, and Clinical Neuroscience, Fifth Edition (Eds. S. Marc Breedlove, Mark R. Rosenzweig and Neil V. Watson),
Sinauer Associates, Inc.
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et al., 2001; Kollins and March, 2007; Swanson and
Volkow, 2009). Research in animals supports this view.
In the SSRT, the stimulant drugs d-amphetamine and
methylphenidate improve stopping performance but only
in rats that perform sluggishly at baseline (Feola et al.,
2000; Eagle and Robbins, 2003; Eagle et al., 2007).
The same stimulant drugs also generally reduce impulsiv-
ity on delay discounting procedures (Richards et al., 1999;
Wade et al., 2000; Isles et al., 2003; Winstanley et al.,
2003; van Gaalen et al., 2006; Adriani et al., 2007;
Floresco et al., 2008) although there have been notable
conﬂicting results as well (e.g. Helms et al., 2006; Staniset al., 2008; Slezak and Anderson, 2009; Wooters and
Bardo, 2011) and there is evidence questioning the spe-
cial role of DA in this process. For example, the ability
of amphetamine to reduce impulsivity on the delay-
discounting procedure is lost in rats depleted of brain
5-HT (Winstanley et al., 2003; Helms et al., 2006). Such
interactions between the DA and 5-HT systems are a
recurring theme in the expression of impulsive behaviour
(Winstanley et al., 2005; Oades, 2007). Moreover, the
eﬀects of stimulants on delay discounting impulsivity have
been shown to depend upon whether delayed rewards
are signalled or not. Thus, amphetamine decreases
impulsivity when delays are signalled (i.e. promotes
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when delays are unsignalled (Cardinal et al., 2000). This
eﬀect is hypothesised to reﬂect the potentiating eﬀects
of stimulants on cues predicting delayed reinforcement
(Cardinal et al., 2000) and may explain some of the dis-
crepancies in the literature on this topic.
Contrasting with the ﬁndings above, when the delay to
reward is ﬁxed and constant, as is generally the case in
the 5-CSRTT, stimulant drugs invariably increase impul-
sivity (Cole and Robbins, 1987; van Gaalen et al., 2006;
Blondeau and Dellu-Hagedorn, 2007). This eﬀect can be
reversed in a less common variant of the 5-CSRTT when
premature responses are recorded but not punished
(Bizarro et al., 2004) as well as in animals showing high
baseline levels of premature responses (Puumala et al.,
1996). Arguably this pattern of eﬀects is consistent with
the rate dependency model used to explain the baseline
dependent eﬀects of stimulant drugs in children with
ADHD (Robbins and Sahakian, 1979). But in the case of
methylphenidate the observed bimodal eﬀects on impul-
sivity may additionally be generated by diﬀerential eﬀects
on noradrenaline and DA availability in the nucleus
accumbens. Low doses of this compound, which aﬀect
locus coeruleus noradrenergic activity (Devilbiss and
Berridge, 2006), decrease impulsivity on the 5-CSRTT
(Pattij et al., 2007), similar to selective noradrenaline
reuptake inhibitors (Robinson et al., 2008b; Pattij et al.,
2012). However, higher doses increase both DA and nor-
adrenaline (Kuczenski and Segal, 1997; Gerasimov et al.,
2000) with increases in DA release thought most likely to
underscore the increase in impulsivity (Cole and Robbins,
1989; van Gaalen et al., 2006).
While the evidence reviewed above questions a singu-
lar involvement of DA in impulsivity it is abundantly clear
that speciﬁc DA receptors play an important modulatory
role in the expression of such behaviour. For example,
the D2/3 antagonist eticlopride when infused in the nucleus
accumbens core completely blocked the impulsive behav-
iour induced by amphetamine on the 5-CSRTT (Pattij et al.,
2007). A similar striking result was obtained in rats made
impulsive by selective lesions of the PFC (Pezze et al.,
2009). Such ﬁndings match recent ﬁndings from Besson
et al. (2010) showing impulsivity to be alleviated by core
infusions of the D2/3 antagonist nafadotride but exacer-
bated by infusions of the same compound in the adjacent
shell sub-region. However, some key challenges lie ahead
in understanding the signiﬁcance of these results. First, it is
unclear exactly what role D2 and D3 receptors play as most
drugs tested have high aﬃnity for both receptors. Second,
identifying the synaptic location of the critical DA receptor
(i.e. pre- or post-synaptic) is virtually impossible in vivo
and would require transgenic approaches not yet available
in rats (e.g. Bello et al., 2011). Third, the pharmacological
ﬁndings discussed above need to be integrated with our
earlier discovery that D2/3 receptors are signiﬁcantly
reduced in number in the ventral striatum (collectively the
core and shell of the nucleus accumbens) of trait impulsive
rats (Dalley et al., 2007).
Resolving these questions has implications for impul-
sive behaviour assessed on delay discounting procedures
and the SSRT, which is also regulated by DA receptors.Just as amphetamine decreases impulsive decision-
making on delay discounting tasks (see above), systemic
administration of D1 and D2 receptor antagonists increase
delay discounting impulsivity (i.e. choices of sooner, smal-
ler rewards: Wade et al., 2000; van Gaalen et al., 2006;
Floresco et al., 2008). This eﬀect may be mediated by
blockade of D1 receptors in medial prefrontal cortex (Loos
et al., 2010) and by D1 and D2 receptors in the orbitofron-
tal cortex (Zeeb et al., 2010). Interestingly, the eﬀects of
D1 and D2 receptor antagonists on impulsivity were only
observed when an explicit cue to the larger delayed
reward was presented (Cardinal et al., 2000; Zeeb
et al., 2010). Through conditioning such cues evidently
engage DA signalling in orbitofrontal cortex and increase
preference of subjects’ for larger delayed rewards (i.e.
they reduce impulsivity). In the absence of such cues,
choice may be governed preferentially by D1 receptors
in medial prefrontal cortex instead. Such ﬁndings reso-
nate with the demonstration that increasing DA transmis-
sion at D1 and D2 receptors favours choice towards larger,
probabilistic rewards, whereas D3 receptor activation has
the opposite eﬀect (St Onge and Floresco, 2009). Intrigu-
ingly, DA may act via D2-like receptors to encourage
risky decisions during so-called near-miss events when
rewards are tantalizingly close (Winstanley et al., 2011).
DA is implicated in the modulation of SSRT from the
eﬃcacy of psychostimulants in ADHD (Tannock et al.,
1989; Feola et al., 2000). Even so, when given systemi-
cally, neither D1 nor D2 receptor antagonists appear to
aﬀect SSRT in rats (Eagle et al., 2007). At ﬁrst glance
such ﬁndings may seem surprising but an increasingly
prominent role for noradrenaline in response inhibition
has been established (Chamberlain et al., 2006; Eagle
et al., 2008), and this eﬀect is thought to have its origins
within prefrontal cortical circuitry (Bari et al., 2011). At
the level of the dorsomedial striatum (homologous to the
caudate in humans), D1 and D2 receptors are reported
to modulate SSRT but in an opposing manner (Eagle
et al., 2011), thereby implicating competing interactions
between the direct (D1 receptor modulated striatonigral
neurons) and indirect (D2 receptor striatopallidal neurons)
pathways in response inhibition.The serotonin systems
The primary ascending serotonergic neurons originate
from the median and dorsal raphe nuclei (see Fig. 2B)
(Dahlstroem and Fuxe, 1964; Azmitia and Segal, 1978)
and make extensive connections with a number of struc-
tures involved in the regulation of impulse control, princi-
pally the ventral tegmental area (VTA), substantia nigra
(SNc), nucleus accumbens (NAcb), hippocampus, amyg-
dala, and prefrontal cortex (Dalley et al., 2011; Hayes and
Greenshaw, 2011). At the synaptic level 5-HT regulates
the activity of many neurotransmitters including DA-con-
taining neurons in the VTA and SNc (McMahon et al.,
2001; Fink and Gothert, 2007; Bubar et al., 2011) and
interactions between 5-HT and DA reportedly contribute
to the expression of certain categories of impulsivity
(Winstanley et al., 2006a) and may even have a bearing
on the aetiology of ADHD (Oades, 2002, 2007).
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ity of globally depleting 5-HT in the brain with the neuro-
toxin 5,7-dihydroxytryptamine (5,7-DHT) infused directly
into the cerebro-ventricular system. Depletion of 5-HT
was accompanied by a selective increase in premature
responding on the 5-CSRTT (Harrison et al., 1997) and
impaired behavioural restraint on a go/no-go task
(Harrison et al., 1999). Consistent with these ﬁndings, rats
administered the 5-HT depleting stimulant, parachloroam-
phetamine, showed impairments on a go/no-go task
(Masaki et al., 2006) and global 5,7-DHT lesions
increased impulsivity on a variant of the 5-CSRTT
(Winstanley et al., 2004). Thus, manipulations that reduce
5-HT function impair the capacity of subjects to inhibit the
initiation of a pre-potent response, a tendency that is
exaggerated when subjects must avoid responding on
explicit no-go trials.
However, the modulation of impulsivity by 5-HT
appears to be heterogeneous and selective for ‘action
restraint’ rather than delay discounting impulsivity or
SSRT (Eagle et al., 2008). Thus, 5-HT depletion studies
in rats have failed to provide convincing evidence that
5-HT contributes to the sensitivity of subjects to delayed
(Winstanley et al., 2003, 2004) or probabilistic (Mobini
et al., 2000b) rewards, but the impact of 5-HT loss on tem-
poral discounting is controversial with some earlier stud-
ies reporting increased impulsivity in rats following
selective 5-HT depletion (Wogar et al., 1993; Bizot
et al., 1999; Mobini et al., 2000a). The reasons for this
divergence of results are unclear but are probably related
to diﬀerences in experimental procedures (see
Winstanley et al., 2006a for further discussion of this
issue). A much clearer set of ﬁndings has been reported
in relation to the SSRT where neither 5-HT depletion
(Eagle et al., 2009) nor selective serotonin reuptake inhib-
itors (Bari et al., 2009) had any major eﬀect on SSRT,
similar to results found in humans (see below and Clark
et al., 2005). This suggests that 5-HT is critical for some
forms of behavioural inhibition but not others.
Further insights have come from the eﬀects of selec-
tive 5-HT agonists and antagonists, which exert both
inhibitory and excitatory eﬀects on impulsivity in rats.
The 5-HT2A/2C agonist (±)-1-(2,5-dimethoxy-4-iodo-
phenyl)-2-aminopropan (DOI) administered systemically
increases impulsivity on both reaction time and delay dis-
counting tasks, an eﬀect blocked by 5-HT2A antagonists
(Evenden and Ryan, 1999; Koskinen et al., 2000;
Blokland et al., 2005; Hadamitzky et al., 2009). The selec-
tive 5-HT2C antagonist SB242084 produced qualitatively
similar eﬀects to DOI on the 5-CSRTT following both sys-
temic (Winstanley et al., 2004; Fletcher et al., 2007) and
intra-NAcb (Robinson et al., 2008a) administration while
the 5-HT2A/2C antagonist SER082 had no eﬀect on
5-CSRTT impulsivity but decreased impulsive responding
on the delay discounting task (Talpos et al., 2006). In a
related study the selective 5-HT2A antagonist M100907
dose-dependently reduced impulsivity on the 5-CSRTT
(Winstanley et al., 2004; Fletcher et al., 2007). The main
brain site of this eﬀect is probably the NAcb (Robinson
et al., 2008a) but 5-HT2A receptor antagonism in the pre-
frontal cortex has also been shown to block impulsivenessevoked on the 5-CSRTT by NMDA receptor antagonism
in the PFC (Carli et al., 2006). The opponent nature of
the serotonergic modulation of impulsivity is further exem-
pliﬁed by the eﬀects of 5-HT1A agonist 8-OH-DPAT which
decreased impulsivity on a choice reaction time task
(Blokland et al., 2005) but increased delay discounting
impulsivity. In the case of the selective 5-HT reuptake
inhibitors, however, the main eﬀects are to reduce
impulsivity on both the 5-CSRTT and the delay
discounting task (Wolﬀ and Leander, 2002; Baarendse
and Vanderschuren, 2012; Dalley et al., unpublished
observations).
Further converging evidence for an involvement of
5-HT in impulsivity was obtained through the direct mea-
surement of 5-HT during performance of rats on a simpli-
ﬁed variant of the 5-CSRTT which loads on response
inhibition (Dalley et al., 2002) and a delay discounting task
(Winstanley et al., 2006b). We found somewhat paradox-
ically that premature responses were positively correlated
with tonic extracellular levels of 5-HT in the medial PFC, a
result seemingly at odds with the eﬀects of globally reduc-
ing or increasing 5-HT function described above but con-
sistent with an earlier study showing up-regulated 5-HT
function in the PFC of impulsive rats (Puumala and Sirvio,
1998). The basis of this paradox is unclear but suggests
that sub-cortical sites may be responsible for the eﬀects
of global 5-HT depletion on impulsivity, possibly through
interactions with the mesolimbic DA system (Robinson
et al., 2008a). In a more recent study extracellular levels
of 5-HT were measured in the PFC and orbitofrontal cor-
tex of rats on a delay discounting task (Winstanley et al.,
2006b). Although hampered by the poor temporal resolu-
tion of intracerebral microdialysis it was striking that 5-HT
levels increased signiﬁcantly in the medial PFC, but not
the OFC during task performance. Arguably the 5-HT
response in the medial PFC may be a neurochemical
corollary of increased neuronal ﬁring in the raphe nucleus
reported recently in rats when rewards are delayed
(Miyazaki et al., 2011). However this does not explain
why rats with increased 5-HT tonus in the PFC are impul-
sive on tasks that load on ‘waiting’ (Dalley et al., 2002;
Robinson et al., 2009) unless one assumes that phasic
5-HT signalling in the PFC is somehow compromised in
these subjects. In any case the dissociation between
medial and orbital frontal 5-HT release during delay
discounting behaviour suggests prominent functional
heterogeneity in the fronto-cortical 5-HT systems.DOPAMINE AND SEROTONIN INFLUENCES ON
IMPULSIVITY IN HUMANS
While the range of experimental techniques and pharma-
cological interventions available to study the neurochem-
ical basis of impulsivity in humans is considerably more
limited than in experimental animals, neurochemical
abnormalities in clinical syndromes associated with impul-
sivity provide importantly complementary insights into the
understanding gained from the preclinical data discussed
above. Although invasive techniques such as in vivo
microdialysis and cyclic voltammetry to measure brain
monoamine levels cannot be performed in humans for
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tomography (PET) have led to great insights into the neu-
rochemistry of impulsivity, adding to data from experimen-
tal psychopharmacology studies and the measurement of
monoamines or their metabolites in urine, plasma or CSF.
Despite such experimental limitations, the picture emerg-
ing from studies of DA, 5-HT and impulsivity in humans
are, on the whole, remarkably consistent with the animal
literature in that diﬀerent types of impulsivity appear to
be modulated diﬀerentially by the diﬀerent monoamines.The dopamine systems
Possibly the most dramatic clinical evidence for an inﬂu-
ence of DA transmission on impulsivity in humans is the
pronounced behavioural change observed in a small pro-
portion (10%) of patients with PD following the adminis-
tration of DA replacement therapies such as levodopa and
agonists at the D2 and D3 receptors: examples include
pramipexole, ropinirole and bromocriptine. In these vul-
nerable patients a number of behavioural syndromes
have been identiﬁed, some, but not all of which meet cri-
teria for Impulse Control Disorders, including: compulsive
gambling and shopping; hypersexuality; and binge eating
(O’Sullivan et al., 2009).
Somewhat surprisingly, on behavioural tests of reward
processing (Housden et al., 2010; Rossi et al., 2010;
Voon et al., 2010a), PD patients who develop these
behaviours do not behave diﬀerently to matched healthy
volunteers. By contrast, on tests of delay discounting
there is good evidence of impatience to delayed rewards
(i.e. increased delay discounting) in these PD patients, at
least in the ‘‘on’’ medication state (Housden et al., 2010;
Voon et al., 2010b). Hence, these data suggest that
D2/D3 receptor signalling contributes to at least some as-
pects of impulsivity, consistent with a report that levodopa
increased in delay discounting in healthy volunteers, an
eﬀect evident in every participant (Pine et al., 2010). How-
ever, in another study the D2/D3 agonist pramipexole was
reported to have no impact on delay discounting, at least
at low-to-moderate doses (Hamidovic et al., 2008), and
others reported no eﬀects of L-dopa on SSRT perfor-
mance (Overtoom et al., 2003; Obeso et al., 2011).
A role for disrupted DA transmission in some clinical
aspects of impulsivity is also supported by studies of
ADHD, though the dominant explanatory framework dif-
fers from that outlined above. Since stimulant medica-
tions, such as methylphenidate and amphetamine,
induce increases in synaptic DA (Kuczenski and Segal,
1997), an inﬂuential model holds that impulsivity in these
individuals is related to lower pre-treatment DA transmis-
sion, at least in the striatum. Consistent with this notion,
individuals with ADHD have reduced CSF levels of the
DA metabolite homovanillic acid (HVA: Shaywitz et al.,
1977), and reduced urinary excretion (Hanna et al.,
1996); paradoxically, however, higher HVA has been
associated with better response to medication in ADHD
(Castellanos et al., 1996).
PET studies of drug-naı¨ve ADHD patients have also
been used to examine this hypothesis, though conﬂicting
ﬁndings have been reported. In one study, greatermethylphenidate-induced DA release, measured using
raclopride displacement, was reported in medication-
naı¨ve ADHD patients relative to healthy volunteers
(Rosa-Neto et al., 2005). In the same sample, there was
a positive relationship between methylphenidate-induced
DA release and commission errors at baseline (Rosa
Neto et al., 2002). However, another study reported the
opposite result, ﬁnding that adults with ADHD had
reduced methylphenidate-induced DA release relative to
healthy volunteers (Volkow et al., 2007). A recent study
from this group also reported lower DAT binding as well
as reduced D2/D3 binding in a large sample of adults with
ADHD (Volkow et al., 2009). Therefore the mechanism by
which DA transmission contributes to the pathogenesis
and treatment of impulsivity in ADHD remains unclear.
Experimental psychopharmacology studies using the
stimulants amphetamine and methylphenidate to investi-
gate the role of DA transmission in impulsivity have also
generated conﬂicting results. This may be driven in part
by their lack of speciﬁcity for the DA system, and likely
concomitant release of other transmitters such as 5-HT.
This complexity is highlighted by theories of ADHD that
propose that the balance between 5-HT and DA transmis-
sion is critical in the aetiology of this disorder (Oades,
2002; Winstanley et al., 2005). de Wit and colleagues
(de Wit et al., 2000, 2002) reported that a high dose
(20 mg) of amphetamine improved SSRT, commission
errors and delay discounting in healthy volunteers; how-
ever, other studies reported conﬂicting results (Kelly
et al., 2006; Acheson and de Wit, 2008). Methylphenidate
has been found to reduce some, but not all, laboratory
measures of impulsivity in ADHD patients (Aron et al.,
2003; Scheres et al., 2003; Turner et al., 2005; DeVito
et al., 2008, 2009). One explanation for this pattern of
results is an ‘‘inverted-U’’ model of response, in which
an optimal amount of DA transmission is required to ade-
quately perform a given cognitive process (Cools and
D’Esposito, 2011). This model may explain why studies
using acute tyrosine and phenylalanine depletion, a
procedure by which DA synthesis can be decreased
by restricting dietary intake of these amino acids
(Montgomery et al., 2003; Leyton et al., 2004), have gen-
erally not reported reliable eﬀects on any measures of
impulsivity (Harmer et al., 2001; McLean et al., 2004;
Lythe et al., 2005; Roiser et al., 2005).
An individual’s position on the ‘inverted-U’, and hence
whether a hypothetical increase in DA transmission might
be likely to make them more or less impulsive or may be
related to environmental factors (e.g. prior stimulant
abuse) or genetic factors (e.g. polymorphisms in genes
aﬀecting DA transmission), or possibly a combination of
the two. Hamidovic and colleagues (Hamidovic et al.,
2009) reported that individuals homozygous for the A
allele at a single nucleotide polymorphism (SNP) in the
D2 receptor gene (rs12364283), which results in reduced
transcription relative to the G allele (Zhang et al., 2007;
SNPs termed T and C respectively in that report), per-
formed less impulsively on the SSRT following amphet-
amine administration, while the converse was true in G
allele carriers. Also consistent with an inverted-U account,
possession of the low-transcription A allele was also
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Recent PET studies have conﬁrmed this pattern,
reporting that lower D2/D3 autoreceptor binding (using
[18F]fallypride) in the midbrain was associated with greater
questionnaire-measured impulsivity (Buckholtz et al.,
2010), replicating an earlier ﬁnding in the caudate in stim-
ulant-dependent individuals (Lee et al., 2009). Stimulant-
dependent individuals, who have lower D2/D3 binding rela-
tive to healthy volunteers (Volkow et al., 2001), are also
reliably more impulsive, whether assessed through behav-
ioural (Monterosso et al., 2005; Clark et al., 2006; Hoﬀman
et al., 2006) or questionnaire (Ersche et al., 2010) mea-
sures. Importantly, increased impulsivity is likely not solely
a consequence of stimulant use, since increased ques-
tionnaire-measured impulsivity is also present in ﬁrst-
degree relatives of stimulant users (Ersche et al., 2010).
In the study by Buckholtz and colleagues discussed above
there was also a positive correlation between question-
naire-measured impulsivity and amphetamine-induced
DA release in the striatum, assessed using raclopride dis-
placement (Buckholtz et al., 2010), though this ﬁnding
conﬂicts with an earlier study, which reported the opposite
result (Oswald et al., 2007). Similarly, elevated striatal DA
release has been reported in PD patients with treatment-
induced pathological gambling (Steeves et al., 2009).
In summary the relationship between DA transmission
and impulsive behaviour is complex, and contradictory
results have been reported. The majority of the question-
naire-based and clinical evidence (i.e. studies in
Parkinson’s disease patients with treatment-induced
impulsivity, substance-dependence and at least some in
ADHD), supports an account by which abnormal trans-
mission at the D2 and D3 receptors contributes to impul-
sivity. However, the evidence from ADHD muddies the
waters somewhat, and the apparently contradictory thera-
peutic eﬀects of DA-releasing stimulant drugs remain dif-
ﬁcult to understand. One possible explanation is that
there is an inverted-U response between DA levels; addi-
tionally, consideration of the critical modulatory role of
5-HT may provide some resolution of this paradox (Oades,
2007). Alternatively, diﬀerent aspects of impulsivity may
contribute to diﬀerent clinical syndromes. This latter
explanation is partly supported by psychopharmacologi-
cal investigations, in which diﬀerent laboratory measures
of impulsivity appear to be diﬀerentially sensitive to exper-
imental DA manipulations: for example, L-dopa appears
to increase delay discounting (Pine et al., 2010), but has
no eﬀect on SSRT performance (Overtoom et al., 2003;
Obeso et al., 2011). It is also possible that clinical syn-
dromes expressing impulsive symptoms result from regio-
nal abnormalities in DA transmission; for example
targeting diﬀerentially the prefrontal and striatal networks.The serotonin systems
Themajority of the clinical data relating 5-HT and impulsiv-
ity have been provided by investigations of suicide. Early
studies reported lower CSF and plasma 5-HIAA levels
(Asberg et al., 1976, 1986) as well as blunted prolactin
response to fenﬂuramine (Mann et al., 1992) in bothsuicide attempters and completers, as well as lower brain
5-HT, 5-HT transporter (5-HTT) and abnormal 5-HT recep-
tor binding at post-mortem in suicide completers (Mann
et al., 2001). Suicide attempters score higher on question-
naire measures of impulsivity (Klonsky and May, 2010) as
well as certain behavioural measures, speciﬁcally prema-
ture responses (Horesh, 2001; Dougherty et al., 2004;
Swann et al., 2005). Importantly this association occurs
across a variety of diﬀerent psychopathologies, including
depression, bipolar disorder and schizophrenia. Research
into individuals with antisocial personality disorder catego-
rised according to whether their violent behaviour was
aggressive or non-aggressive has revealed similar results,
with impulsive aggressive individuals reported to have low-
er levels of CSF 5-HIAA (Linnoila et al., 1983) and blunted
prolactin response to fenﬂuramine (Coccaro et al., 1989;
Dolan et al., 2002). This latter eﬀect has also reported in
ﬁrst degree relatives of individuals with antisocial personal-
ity disorder (Coccaro et al., 1994), in individuals with bor-
derline personality disorder (Soloﬀ et al., 2003), and in
impulsive men without a personal or familial psychiatric
history (Manuck et al., 1998).
The link between 5-HT and impulsivity in suicide
attempters has also been assessed more directly using
PET, where reduced 5-HTT levels were reported speciﬁ-
cally in more impulsive suicide attempters as assessed
by questionnaire measures (Lindstrom et al., 2004;
Ryding et al., 2006). At ﬁrst glance, this relationship,
which was not evident in healthy volunteers, may seem
paradoxical as, assuming that the same number of 5-HT
terminals are present, reduced 5-HTT should increase
synaptic 5-HT; however, it is also possible that this ﬁnding
may reﬂect a reduced density of 5-HT terminals. A similar
reduction in 5-HTT binding in impulsive aggressive
individuals has also been reported (Frankle et al., 2005).
Another link between suicide and 5-HT, though more
indirect, comes from reports of small but statistically
signiﬁcant increased rates of suicide in depressed adoles-
cents prescribed SSRIs (Hetrick et al., 2007). Again, this
ﬁnding is somewhat inconsistent with other data, since
the pharmacological action of SSRIs is to increase 5-HT
transmission. Moreover, a small number of studies
reported that SSRIs reduced clinical measures of impul-
sivity in patients with personality disorders (Soloﬀ, 1997;
Butler et al., 2010; Silva et al., 2010), though others found
no such beneﬁcial eﬀect (Moeller et al., 2001; Rinne et al.,
2002).
The most widely utilised experimental technique to
investigate the role of 5-HT transmission in impulsivity in
humans is acute tryptophan depletion. Similar to acute
tyrosine and phenylalanine depletion, participants ingest
an amino acid mixture selectively lacking tryptophan,
the precursor to 5-HT, resulting in a robust reduction in
synthesis (Williams et al., 1999). Numerous studies have
reported that acute tryptophan depletion increases a vari-
ety of behavioural measures of impulsivity as assessed
using a variety of measures, including: premature
responses (LeMarquand et al., 1998, 1999; Walderhaug
et al., 2002, 2007; Booij et al., 2006; Dougherty et al.,
2007); impaired conditioned suppression (Crockett
et al., 2009; Robinson et al., 2012); and delay discounting
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consistent with data in experimental animals, tryptophan
depletion has generally not been found to impair SSRT
(Clark et al., 2005), other than possibly in individuals with
a family history of impulse control disorders (Crean et al.,
2002). The reported eﬀects of tryptophan depletion on ris-
ky decision-making have been inconsistent (Rogers et al.,
1999; Anderson et al., 2003; Talbot et al., 2006).
A few studies have investigated the eﬀect of boosting
5-HT transmission on impulsivity, using either SSRIs or
fenﬂuramine; unfortunately this latter compound is no
longer available for research in humans following its with-
drawal from the market due to concerns over heart dis-
ease. Fenﬂuramine was found to reduce delay
discounting in males with (Cherek and Lane, 1999,
2001) but not those without (Cherek and Lane, 2000) a
history of conduct disorder. Similar results were reported
for chronic SSRI treatment (Cherek et al., 2002). The
5-HT1A agonist buspirone has not been found to alter
impulsivity in humans (Chamberlain et al., 2007), but the
5-HT2A antagonist quetiapine was found to decrease both
questionnaire-measured impulsivity and Stroop interfer-
ence in individuals with borderline personality disorder
(Van den Eynde et al., 2008).
There is a substantial literature investigating cognitive
deﬁcits in recreational users of the drug 3,4-methylenedi-
oxymethamphetamine (MDMA or ‘ecstasy’), which
acutely releases but may in the long term deplete 5-HT
(see Green et al., 2003 for a review). Many of these stud-
ies also included assessments of impulsivity. However,
such studies are complicated by the potential for pre-
existing diﬀerences between groups or the possible
impact of drugs other than ecstasy. Like other drug users,
ecstasy users score higher than non-drug-using controls
on questionnaire-based impulsivity measures (Morgan,
1998; Morgan et al., 2002; Butler and Montgomery,
2004; Schilt et al., 2010), and also some behavioural
measures (Morgan et al., 2006; Quednow et al., 2007).
These group diﬀerences have even been observed in
chronic ecstasy users with minimal exposure to other
drugs (Halpern et al., 2004, 2011). It is possible that this
association may reﬂect pre-existing diﬀerences between
groups, since recreational users of drugs other than
ecstasy also tend to have elevated scores on such ques-
tionnaires (Roiser et al., 2007). Indeed, in one study
ecstasy users performed less impulsively than cannabis
users, and similarly to non-drug-using controls, on a test
of information-sampling impulsivity (Clark et al., 2009).
A number of studies have examined whether func-
tional polymorphisms impacting on 5-HT transmission
may inﬂuence impulsivity in humans. A polymorphism in
the 5-HT transporter gene (5-HTTLPR), which alters tran-
scription in vitro (Hu et al., 2006) and prolactin response
to fenﬂuramine in vivo (Reist et al., 2001) has been exam-
ined most frequently. The s allele at this locus is believed
to result in reduced 5-HT transmission relative to the l
allele. Some studies have reported that the s allele is
over-represented in individuals with antisocial personality
disorder (Sakai et al., 2006). The s allele has also been
associated with increased premature responding in men
(Walderhaug et al., 2010), though conﬂicting ﬁndingshave been reported (Lage et al., 2011; Malloy-Diniz
et al., 2011).
Other studies have examined polymorphisms in the
tryptophan hydroxylase-2 (TPH2) gene. One found an
association with SSRT in healthy volunteers (Stoltenberg
et al., 2006); another reported an association with ques-
tionnaire-measured impulsivity in adolescents with
ADHD, though the polymorphisms implicated did not
overlap with those identiﬁed in the former study (Oades
et al., 2008). However, one of the TPH2 polymorphisms
reported in the latter study (rs6582071) has been associ-
ated with reduced brain 5-HT synthesis in humans (Booij
et al., 2011), lending credence to this association. Finally,
a recent study reported that a polymorphism in the 5-HT2B
gene, which is exclusive to the Finnish population and
completely blocks expression of the receptor, is associ-
ated with antisocial and borderline personality disorders
(Bevilacqua et al., 2010). While no behavioural or ques-
tionnaire measures of impulsivity were administered to
the patients in this study, follow-up studies in 5-HT2B
knockout mice in the same paper revealed elevated
impulsivity on a delay discounting measure.
In summary, while fewer studies are available, the
human experimental and clinical data relating abnormal
5-HT transmission to impulsivity are quite consistent:
most studies report that impulsivity is related to lower
5-HT transmission. However, as with the literature
examining DA, not all measures of impulsivity are equally
aﬀected. Few studies of speciﬁc 5-HT receptors, either
through psychopharmacological or PET investigations,
have been reported, and more work is needed in this
area.
CONCLUSIONS
The clinical and preclinical data reviewed above are nota-
ble for their consistency. First, as outlined in the introduc-
tion, it is clear that ‘‘impulsivity’’ is not a single
psychological construct. As noted by numerous previous
authors (Evenden, 1999b; Moeller et al., 2001; Winstanley
et al., 2004), there are several diﬀerent dimensions of
impulsivity, with many commonalities between the clinical
and preclinical literature. For example, 5-HT depletion,
whether via acute tryptophan depletion in humans or
selective neurotoxic lesions in rats, appears to have little
eﬀect on certain forms of motoric inhibitory control (e.g.
as measured by the SSRT), but reliably increases the
likelihood of premature responding. SSRT performance
is similarly unaﬀected by DA agonists and L-dopa in
humans, and when administered systemically in rats, the
same drugs increase delay discounting. Together with
the dissociations noted in factor analyses of human
behavioural data, these ﬁndings strongly indicate that
‘‘impulsivity’’ is a multi-faceted phenomenon.
Second, it is increasingly clear, especially from pre-
clinical data, that a simple monotonic inﬂuence of either
DA or 5-HT on any given aspect of impulsivity is unlikely.
Indeed in the case of DA, both clinical and preclinical data
suggest that ‘‘inverted-U’’ shape curve may exist. More-
over, the diversity of eﬀects of agonists and antagonists
at receptor subtypes of these two monoamines is striking:
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increases premature responses on 5-CSRTT, while the
selective 5-HT2A antagonist M100907 reduces impulsivity
on the same measure (Winstanley et al., 2004; Fletcher
et al., 2007). However, further work is needed in human
studies to assess whether similar dissociations can be
identiﬁed.
Finally, though a great deal of research over the past
decade has focused on the role of DA in impulsivity, a
return to 5-HT seems warranted. In particular it will be
important to characterise further the nature of interactions
between DA and 5-HT in inﬂuencing diﬀerent types of
impulsivity (Winstanley et al., 2005; Oades, 2007). Such
research might help to resolve the paradox of why
DA-releasing stimulant medications improve symptoms
of ADHD, while at the same time drugs that boost DA
transmission (agonists or L-dopa) appear to increase
impulsivity, most dramatically in the case of medication-
induced side-eﬀects in PD. At the same time, it must be
appreciated that other neurotransmitters also aﬀect
impulsivity. For example, SSRT performance in humans
is modulated by manipulations of the noradrenergic
system (Chamberlain and Sahakian, 2007), mu-opioid
receptor function predicts impulsivity both in humans
(Love et al., 2009) and mice (Olmstead et al., 2009),
whilst GABA levels in dorsolateral prefrontal cortex
are reportedly decreased in impulsive individuals (Boy
et al., 2011). Improving our understanding of the interac-
tions between these transmitters, and providing a more
cognitively-informed nosology of impulsivity, may provide
important insights into the aetiology of highly disabling
syndromes such as ADHD, stimulant dependence and
bipolar disorder.FINANCIAL DISCLOSURE
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